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Abstract: Increasing safety while maintaining or even augmenting efficiency are the main goals of research
for novel vaccine development and improvement of treatment schemes in allergen immunotherapy (AIT).1,
2, 3, 4 In spite of encouraging positive experiences,5 AIT still faces several problems related to worldwide
standardization, its limited efficacy, potential severe side effects, low patient adherence, high costs, and
long duration (3–5 years) of treatment. There have been many different approaches to improve the
standardization, efficacy, and safety of AIT in the past, which have been continuously pursued during
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asthma,9 allergic rhinoconjunctivitis,10 bee venom allergy,11 and food allergy.12 Similar efforts are being
undertaken for autoimmune diseases. Studies to offer prophylactic usage are also being performed.13
Regulatory issues represent an important aspect in this context14 and global and national strategies are
being continuously developed.15,16 It is essential to develop strong collaborations with the regulatory
authorities for extensive preventive usage of AIT vaccines and usage of pollen chambers for outcome
evaluations to avoid slowing down of vaccine developments. Here, the authors summarize some current
investigations aiming at further improvement of AIT vaccines (Table 1).
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INTRODUCTION
Increasing safety while maintaining or even augmenting efficiency are the main goals
of research for novel vaccine development and improvement of treatment schemes in
allergen immunotherapy (AIT).1–4 In spite of encouraging positive experiences,5 AIT
still faces several problems related to worldwide standardization, its limited efficacy,
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KEY POINTS
 The current aim is to improve allergen immunotherapy (AIT) to shorten duration of treat-
ment, enhance efficiency, reduce side effects, and, ultimately, significantly increase the
utilization of this curative treatment of allergy with high patient adherence and compliance.
 To increase the efficacy of AIT, allergens have been modified to facilitate their uptake and
presentation, or have been coupled to innate immunostimulatory substances. New adju-
vants have also been introduced recently.
 Hypoallergenic molecules (eg, allergoids and recombinant allergen peptides) have been
developed to improve the safety profile of the vaccines.
 Administration of recombinant IgG4 antibodies is a new, quick, passive immunization AIT
strategy with remarkable efficiency.
 Recent mouse experiments suggest that it may be possible to develop AIT even for pre-
natal allergy prevention.
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potential severe side effects, low patient adherence, high costs, and long duration (3–
5 years) of treatment. There have been many different approaches to improve the
standardization, efficacy, and safety of AIT in the past, which have been continuously
pursued during the past years.6–8 Currently, efforts on developing novel vaccines of
AIT continue for the treatment of asthma,9 allergic rhinoconjunctivitis,10 bee venom al-
lergy,11 and food allergy.12 Similar efforts are being undertaken for autoimmune dis-
eases. Studies to offer prophylactic usage are also being performed.13 Regulatory
issues represent an important aspect in this context14 and global and national strate-
gies are being continuously developed.15,16 It is essential to develop strong collabora-
tions with the regulatory authorities for extensive preventive usage of AIT vaccines and
usage of pollen chambers for outcome evaluations to avoid slowing down of vaccine
developments. Here, the authors summarize some current investigations aiming at
further improvement of AIT vaccines (Table 1).
NOVEL ALLERGEN FORMULATIONS AND ADJUVANTS
Adjuvants are add-on constituents of the vaccines, ideally increase the immunoge-
nicity of the allergens to induce a quicker, stronger, and longer-lasting immune
response; meanwhile also modulate the immune response to enhance allergen-
specific T regulatory cell differentiation, immunoglobulin (Ig)G4 antibody production,
and, importantly, avoid TH2-type response as well as anaphylaxis.
Coupling of allergens to innate immunostimulatory substances is primarily aimed at
improving vaccine efficiency. These strategies include CpG oligonucleotide-
conjugated allergens,17 allergens coupled to viruslike particles,18,19 carbohydrate-
based particles,20 and the use of monophosphoryl lipid A formulated with allergoid.21
Encapsulation of allergens in nanoparticles enables us to design the immunomodula-
tory and depot effect of a complex vaccine very precisely.22,23 Nanoparticles can have
an adjuvant effect themselves (eg, viruslike particles), or various adjuvant molecules
can be conjugated to or packed in the particles (eg, Vibrio cholerae neuraminidase
on synthetic microparticles), and the physical-chemical characteristics of the particles
determine the kinetics of the antigen release (eg, liposomes). Liposomes and micro-
crystalline tyrosine are promising new alternatives of the widely used aluminum hy-
droxide (alum) adjuvant.
Sublingual administration of an allergen together with a-galactosylceramide-lipo-
somes increased the therapeutic performance of the vaccine in mouse model of
allergic rhinitis.24 High-affinity glycan ligand of the inhibitory receptor CD33 and the
allergen, packed in liposomal nanoparticles, was able to suppress immunoglobulin
(Ig)E-mediated activation of mast cells and, thus, was shown to be efficient in prevent-
ing anaphylaxis in transgenic mice bearing human CD33-expressing mast cells.25
Such approaches may help to increase the safety of AIT.
Microcrystalline tyrosine, an alternative depo adjuvant composed of nonessential
amino acid L-tyrosine, is a second-generation adjuvant currently used for AIT in
humans (eg, Pollinex, Acarovac Plus).26 It is proven to be safe for human use,27 and
efficiently induces IgG4 production and reduces symptoms in house dust mite
(HDM) subcutaneous immunotherapy (SCIT).26
Microcrystalline tyrosine-adsorbed grass pollen allergoid (Pollinex quattro)
enhanced with monophosphoryl lipid A, a second-generation immunomodulatory
adjuvant, had a beneficial long-term effect as well.28
Recombinant allergen peptides, selected to have advantageous safety profile are
generally less immunogenic. Therefore, various carrier systems, typically of microbi-
al origin, have been developed.29 Promising new approaches include Vibrio cholerae
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Table 1
Novel AIT vaccine developmental strategies currently being pursued
Type of the Vaccine/Approach References
Coupling of allergens to innate immunostimulatory substances
CpG oligonucleotide-conjugated allergens 17
Allergens coupled to viruslike particles 18,19,32,33
Carbohydrate-based particles 20
Vibrio cholerae neuraminidase on allergen-loaded synthetic
microparticles
29
Fusion of nonallergenic peptides and PreS protein from hepatitis B virus 34,35
Fusion of nonallergenic peptides and tetanus toxoid 36
Novel adjuvants
Monophosphoryl lipid A formulated with allergoid 21
Microcrystalline tyrosine 26,27
Proteoliposome adjuvant from Neisseria meningitidis 30
a-Galactosylceramide containing liposomes 24
Encapsulation of allergens in micro-/nanoparticles
Carbohydrate-based particles 20
a-Galactosylceramide containing liposomes 24
CD33 ligand and the allergen packed in liposomal nanoparticles 25
V cholerae neuraminidase on allergen-loaded synthetic microparticles 29
Allergoids and recombinant allergens
Monophosphoryl lipid A formulated with allergoid 21
Allergen extracts modified with glutaraldehyde 40
Fusion of nonallergenic peptides and PreS protein from hepatitis B virus 34,35
Fusion of nonallergenic peptides and tetanus toxoid 36
Recombinant T-cell epitope peptides 43
Allergen fragments 44
Recombinant allergen hybrids 45
Conjugation of allergoids to nonoxidized mannan 51,52
Fusion of allergens with other immune response modifiers
CD33 ligand and the allergen packed in liposomal nanoparticles 25
MAT-vaccine 37,38
Conjugation of allergoids to nonoxidized mannan 51,52
Novel routes of administration
Intralymphatic AIT 37,38,60
Epicutaneous AIT 59
Combination of AIT with biologicals
Administration of anti-IgE 55–58
Novel administration protocols
Passive immunization 69
Prenatal preventive vaccination 68,70
Considering that certain approaches may include different strategies, some of the vaccines are
mentioned in multiple categories.
Abbreviations: AIT, allergen immunotherapy; Ig, immunoglobulin; MAT, modular antigen
translocation.
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neuraminidase, as an immunomodulatory agent, on allergen-loaded synthetic micro-
particles30; proteoliposome from Neisseria meningitidis as an adjuvant for HDM al-
lergy vaccine31; and utilization of viruslike particles to enhance uptake of the
allergen by antigen-presenting cells.32 A single dose of allergen Fel d 1-linked virus-
like particles is able to prevent type I hypersensitivity response in mice.33,34 Fusion
proteins consisting of nonallergenic peptides from the 4 major timothy grass pollen
allergens and the PreS protein from hepatitis B virus as a carrier efficiently reduced
T-cell proliferation and proinflammatory cytokine release, while increased blocking
IgG activity.35 Engineered recombinant fusion proteins consisting of nonallergenic
peptides of the allergens and microbial components, like hepatitis B PreS protein36
or partial fragment of a tetanus toxoid molecule,37 seems to be safe and efficient in
model systems.
In a novel approach, the major cat allergen (Fel d 1) was modified in a way that its
uptake and presentation by professional antigen-presenting cells was highly
improved. Human immunodeficiency virus transacting activator of transcription
(TAT)-derived membrane translocation domain was used to enhance entry to cells,
and a truncated peptide of the invariant chain was used to increase antigen presen-
tation.38,39 This modular antigen translocation (MAT)-Fel d 1 vaccine is efficiently
internalized and potently presented to T cells by antigen-presenting cells, which
stimulated T-cell responses in 100 times lower doses compared with native aller-
gens. In a double-blind, placebo-controlled clinical trial, the MAT-Fel d 1 vaccine
was administered in 3 increasing doses into inguinal lymph nodes at 4-week inter-
vals. In addition to a good safety profile, only 3 doses of MAT-Fel d 1 intra-lymph
node vaccination induced clinical tolerance to nasal cat allergen challenge in par-
allel with T-cell tolerance and increased serum IgG4 and interleukin (IL)-10
levels.38,39 Currently this approach is being pursued for veterinary vaccine
development.
ALLERGOIDS, RECOMBINANT ALLERGENS
Targeting T cells to induce T-cell tolerance and bypassing IgE binding to avoid IgE-
mediated side effects is an essential approach in AIT.40 To improve AIT safety, the pri-
mary aim is to use hypoallergenic molecules to prevent severe complications such as
anaphylaxis. Currently, there are many modified allergen preparations (allergoids) in
the market with decreased IgE binding activity. Chemical modification of allergen ex-
tracts (eg, with glutaraldehyde41) aims to prevent IgE cross-link with conformational
epitopes, while linear epitopes are preserved. To accomplish this aim, several suc-
cessful new approaches have been developed,42,43 including mixture of T-cell epitope
peptides,44 allergen fragments,45 fusion proteins,36,37 and recombinant allergen hy-
brids.46 The prototype of this approach is peptide immunotherapy that uses linear
T-cell epitope peptides, and has shown promising results,47,48 although it still faces
challenges in phase III clinical trials.49–51 All of these allergoid preparations enable
the administration of the allergens in higher doses to efficiently induce T-cell tolerance
without the risk of anaphylaxis.40 Conjugation of allergoids to nonoxidized mannan fa-
cilitates their uptake by antigen-presenting cells.52,53
Some of the clinically significant allergens, however, may be poorly represented
in allergen extracts. Development of molecular vaccines, based on recombinant
allergen components, helps to overcome the limitations of the vaccines based on
natural allergen extracts.54 Identification of immunodominant molecular compo-
nents of the allergens is an important initial step of the development of such AIT
approaches.55
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ADD-ON THERAPIES AND NEW PROTOCOLS
Combination of conventional or novel methods of AIT with biological immune
response modifiers is a promising new therapeutic approach. Anti-IgE combined
with AIT has been evaluated in several studies. Significant decrease in the risk of
anaphylaxis and improved rescue medication scores were observed during rush
immunotherapy with a quicker dose increment and reach of the maintenance
dose.56,57 Accumulating evidence suggests that anti-IgE treatment is a valuable
add-on to AIT for airway allergies, especially to prevent adverse events in the build-
up phase and improve safety profile in cases in which the designated maintenance
dose is not tolerated by the patient.58,59 Other possible combinations include anti-
IL-4 or anti-IL-13 as well as their receptor antagonists.
Different routes of vaccine administration also have been proposed to improve ef-
ficacy and safety. Intralymphatic vaccination and epicutaneous vaccination are
recently pursued novel strategies. Both showed similar efficacy to SCIT in grass pollen
allergy, however, that has been reached with fewer injections and lower total allergen
doses.60 Intralymphatic administration induces T-cell tolerance or strong TH1 re-
sponses depending on the type of vaccine used.39,61
Meta-analysis of the double-blind, placebo-controlled trials has shown that sublin-
gual immunotherapy (SLIT) is safe and clinically efficacious with a treatment benefit
approximately half of that achieved with SCIT.62 Disease-modifying effects of SLIT
have been confirmed in large-scale randomized, double-blind, placebo-controlled tri-
als also in children63–68; and even its preventive administration has been proposed.69
In an exciting, current study, cat-allergic patients were treated with a single dose of
2, fully human, recombinant IgG4-blocking antibodies specific for Fel d 1, the major cat
allergen. This treatment resulted in a rapid and sustained reduction in clinical symp-
toms after nasal allergen provocation test, suggesting a new, quick, passive AIT strat-
egy for allergies.70 Treatment-emergent adverse events were closely monitored during
the study, and there was neither any difference in the frequency of the adverse events
between antibody-treated and placebo group, nor did any severe adverse event occur
in relation to the IgG4 antibody treatment.
70
In a recent mouse experiment, the administration of anti-IgE antibody during preg-
nancy caused long-term IgE-class–specific immunosuppression in the offspring that
was able to prevent allergic sensitization. These results suggest that it may be
possible to develop a vaccination strategy aiming prenatal allergy prevention.71
Fig. 1. Strategies for development of a more safe, efficient, and reliable vaccine for AIT.
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SUMMARY
Intensive efforts have been invested to improve AIT vaccines by making them more
efficient, convenient, and safe2,16 (Fig. 1). Still, fewer than 10% of allergic patients
choose to receive AIT.72 Besides the fear from potential side effects and poor adher-
ence due to long duration of treatment,73 the possible cause of weak overall,
population-wide efficiency of AIT is that not all the potential influencing factors were
considered during the development of AIT strategies, because of lack of knowledge.
Identification of good biomarkers predicting beneficial vaccine immune response is
still an unmet clinical need; however, it is under intensive investigation.74 Better under-
standing of the immune response to vaccines will hopefully enable us to develop more
efficient AIT strategies specifically tailored to allergic disease endotypes.75
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